The Evaluation of Tumor-infiltrating Lymphocytes (TILs) in Breast Cancer: Recommendations by an International TILs Working Group 2014

Overview

Journal Ann Oncol

Publisher Elsevier

Specialty Oncology

Date 2014 Sep 13

PMID 25214542

Citations 1379

Authors

R Salgado

C Denkert

S Demaria

N Sirtaine

F Klauschen

G Pruneri

S Wienert

G Van den Eynden

F L Baehner

F Penault-Llorca

E A Perez

E A Thompson

W F Symmans

A L Richardson

J Brock

C Criscitiello

H Bailey

M Ignatiadis

G Floris

J Sparano

Z Kos

T Nielsen

D L Rimm

K H Allison

J S Reis-Filho

S Loibl

C Sotiriou

G Viale

S Badve

S Adams

K Willard-Gallo

S Loi

Affiliations

Soon will be listed here.

Abstract

Background: The morphological evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer (BC) is gaining momentum as evidence strengthens for the clinical relevance of this immunological biomarker. Accumulating evidence suggests that the extent of lymphocytic infiltration in tumor tissue can be assessed as a major parameter by evaluation of hematoxylin and eosin (H&E)-stained tumor sections. TILs have been shown to provide prognostic and potentially predictive value, particularly in triple-negative and human epidermal growth factor receptor 2-overexpressing BC.

Design: A standardized methodology for evaluating TILs is now needed as a prerequisite for integrating this parameter in standard histopathological practice, in a research setting as well as in clinical trials. This article reviews current data on the clinical validity and utility of TILs in BC in an effort to foster better knowledge and insight in this rapidly evolving field, and to develop a standardized methodology for visual assessment on H&E sections, acknowledging the future potential of molecular/multiplexed approaches.

Conclusions: The methodology provided is sufficiently detailed to offer a uniformly applied, pragmatic starting point and improve consistency and reproducibility in the measurement of TILs for future studies.

Citing Articles

Molecular subtyping and target identification in triple negative breast cancer through immunohistochemistry biomarkers.

Bouzid R, Bouzid R, Labed H, Serhani I, Hellal D, Oumeddour L BMC Cancer. 2025; 25(1):454.

PMID: 40082760 PMC: 11905517. DOI: 10.1186/s12885-025-13832-7.

Population-specific patterns in assessing molecular subtypes of young black females with triple-negative breast cancer.

Rajagopal P, Reid S, Fan R, Venton L, Weidner A, Roberson M NPJ Breast Cancer. 2025; 11(1):28.

PMID: 40069179 PMC: 11897140. DOI: 10.1038/s41523-025-00731-0.

Therapeutic potential of triple-negative breast cancer immune checkpoint blockers: A 21-year bibliometric analysis.

Sun Z, Liu C, Yao Y, Gao C, Li H, Wang L Medicine (Baltimore). 2025; 104(10):e41739.

PMID: 40068043 PMC: 11903016. DOI: 10.1097/MD.0000000000041739.

Automated deep learning-based assessment of tumour-infiltrating lymphocyte density determines prognosis in colorectal cancer.

Millward J, He Z, Nibali A, Mouradov D, Mielke L, Tran K J Transl Med. 2025; 23(1):298.

PMID: 40065354 PMC: 11892243. DOI: 10.1186/s12967-025-06254-3.

PTEN inactivating mutations are associated with hormone receptor loss during breast cancer recurrence.

Zhan H, Antony V, Tang H, Theriot J, Liang Y, Hui P Breast Cancer Res Treat. 2025; .

PMID: 40063317 DOI: 10.1007/s10549-025-07660-3.

References

Qi W, Huang X, Wang J . Correlation between Th17 cells and tumor microenvironment. Cell Immunol. 2013; 285(1-2):18-22. DOI: 10.1016/j.cellimm.2013.06.001. View

Gobert M, Treilleux I, Bendriss-Vermare N, Bachelot T, Goddard-Leon S, Arfi V . Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res. 2009; 69(5):2000-9. DOI: 10.1158/0008-5472.CAN-08-2360. View

Bates G, Fox S, Han C, Leek R, Garcia J, Harris A . Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol. 2006; 24(34):5373-80. DOI: 10.1200/JCO.2006.05.9584. View

Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D . Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol. 2014; 25(8):1544-50. DOI: 10.1093/annonc/mdu112. View

Demaria S, Volm M, Shapiro R, Yee H, Oratz R, Formenti S . Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy. Clin Cancer Res. 2001; 7(10):3025-30. View

Bendall S, Simonds E, Qiu P, Amir E, Krutzik P, Finck R . Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum. Science. 2011; 332(6030):687-96. PMC: 3273988. DOI: 10.1126/science.1198704. View

West N, Milne K, Truong P, Macpherson N, Nelson B, Watson P . Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. Breast Cancer Res. 2011; 13(6):R126. PMC: 3326568. DOI: 10.1186/bcr3072. View

Galon J, Angell H, Bedognetti D, Marincola F . The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity. 2013; 39(1):11-26. DOI: 10.1016/j.immuni.2013.07.008. View

Coussens L, Pollard J . Leukocytes in mammary development and cancer. Cold Spring Harb Perspect Biol. 2010; 3(3). PMC: 3039933. DOI: 10.1101/cshperspect.a003285. View

10.

Mahmoud S, Paish E, Powe D, Macmillan R, Grainge M, Lee A . Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol. 2011; 29(15):1949-55. DOI: 10.1200/JCO.2010.30.5037. View

11.

Oda N, Shimazu K, Naoi Y, Morimoto K, Shimomura A, Shimoda M . Intratumoral regulatory T cells as an independent predictive factor for pathological complete response to neoadjuvant paclitaxel followed by 5-FU/epirubicin/cyclophosphamide in breast cancer patients. Breast Cancer Res Treat. 2012; 136(1):107-16. DOI: 10.1007/s10549-012-2245-8. View

12.

Pardoll D . The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012; 12(4):252-64. PMC: 4856023. DOI: 10.1038/nrc3239. View

13.

West N, Kost S, Martin S, Milne K, Deleeuw R, Nelson B . Tumour-infiltrating FOXP3(+) lymphocytes are associated with cytotoxic immune responses and good clinical outcome in oestrogen receptor-negative breast cancer. Br J Cancer. 2012; 108(1):155-62. PMC: 3553524. DOI: 10.1038/bjc.2012.524. View

14.

Liu S, Foulkes W, Leung S, Gao D, Lau S, Kos Z . Prognostic significance of FOXP3+ tumor-infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration. Breast Cancer Res. 2014; 16(5):432. PMC: 4303113. DOI: 10.1186/s13058-014-0432-8. View

15.

Gajewski T, Schreiber H, Fu Y . Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013; 14(10):1014-22. PMC: 4118725. DOI: 10.1038/ni.2703. View

16.

Liu S, Lachapelle J, Leung S, Gao D, Foulkes W, Nielsen T . CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer. Breast Cancer Res. 2012; 14(2):R48. PMC: 3446382. DOI: 10.1186/bcr3148. View

17.

Adams S, Gray R, Demaria S, Goldstein L, Perez E, Shulman L . Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 2014; 32(27):2959-66. PMC: 4162494. DOI: 10.1200/JCO.2013.55.0491. View

18.

Nabholtz J, Abrial C, Mouret-Reynier M, Dauplat M, Weber B, Gligorov J . Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact. Ann Oncol. 2014; 25(8):1570-7. DOI: 10.1093/annonc/mdu183. View

19.

DeNardo D, Barreto J, Andreu P, Vasquez L, Tawfik D, Kolhatkar N . CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell. 2009; 16(2):91-102. PMC: 2778576. DOI: 10.1016/j.ccr.2009.06.018. View

20.

Dieci M, Criscitiello C, Goubar A, Viale G, Conte P, Guarneri V . Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. Ann Oncol. 2014; 25(3):611-618. PMC: 3933248. DOI: 10.1093/annonc/mdt556. View